Retatrutide research listings: names, formats and price checks

Retatrutide is identified in Lilly’s development pipeline as LY3437943, a compound acting at GIP, GLP-1 and glucagon receptors. That developer record identifies the compound under investigation. It does not authenticate a third-party supplier’s vial, establish equivalence with study material, or verify a retail listing.

Lilly: official clinical development pipeline

Check the full supplier specification

Suppliers may use shortened names or catalogue labels alongside “retatrutide.” An alias alone is insufficient evidence that a product contains the named compound. Check the product specification and the corresponding laboratory report. If a title and description disagree, request clarification rather than inferring the identity from price or a similar product name.

Keep forms and package amounts distinct

A single-vial comparison should preserve the labeled amount per vial. A multi-item bundle, pen, spray or blend belongs in a separate comparison unless the exact composition, physical form and package quantity are all matched. A lower package price can reflect less material or a different format.

Compare current retatrutide research prices

View separately catalogued retatrutide oral spray listings

Find the relevant price for your market

Open the current comparison and choose the amount and form you are assessing. Read the vendor’s source timestamp and stock state, then confirm the product option and original currency on its site. The comparison does not automatically turn every affiliate code into a price reduction.

How price observations and coupon checks differ

Check current coupon status by vendor

Use the compound comparison carefully

Retatrutide, tirzepatide and semaglutide have separate catalogue records. A side-by-side supplier comparison is a comparison of listed products and prices; it does not mean those compounds are interchangeable or support a treatment choice.

Compare Tirzepatide research listings

Compare Semaglutide research listings

Read a report for identity, measured amount and analytical scope

PeptideTech’s research listings are not a route to prescribed care. This guide contains no dosing or use instructions and does not endorse the use of third-party research products in people or animals.

Correction and sources

The old article quoted a fixed American Peptides price after TECH10 and promised weekly rechecks. Those claims were unsupported by the current vendor record. The revised article points to dated offers and treats compound identity, affiliate status and research listings separately.

Editorial revision: 17 September 2026. The original publication date is preserved. Offer observation dates, laboratory report dates and coupon checks are separate from this editorial date.